Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)


30 Sep 2019


Poster Display session 3



Tumour Site



Philippe Saiag


Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255


P. Saiag1, L. Mortier2, C. Dutriaux3, L. Benmahammed4, O. Morsli5, C. Train6, A. Spampinato4, M.T. Leccia7, N. Meyer8, J.J. Grob9

Author affiliations

  • 1 Dermatology And Oncology, Université de Versailles Saint Quentin en Yvelines, 92104 - Boulogne/FR
  • 2 Dermatology And Oncology, Hopital Claude Huriez, 59037 - Lille/FR
  • 3 Dermatology And Paediatric Dermatology, CHU Bordeaux - Hopital St. André, 33000 - Bordeaux/FR
  • 4 Clinical Research, MSD France, 92400 - Courbevoie/FR
  • 5 Clinical Research, MSD France, 92418 - Courbevoie/FR
  • 6 Clinical Research, ClinSearch, 92245 - MALAKOFF/FR
  • 7 Dermatology And Oncology, CHU Albert Michalon, 38700 - La Tronche/FR
  • 8 Medical Oncology-skin, IUCT–Oncopole, 31059 - Toulouse/FR
  • 9 Dermatology And Oncology, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, 13009 - Marseille/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4130


Information on outcomes after cessation of anti-PD-1 mAb for CR are scarce outside KN-001 & 006 trials. We investigated these outcomes in the French pembro EAP, where pts were less selected than in registration trials.


A multicenter ambispective cohort of advanced melanoma pts initiating pembro between May 2014-Sept 2015 (CCTIRS, #15.640) was searched for pts who achieved CR. Overall and progression-free survivals with Log rank tests were used to compare curves.


687 pts (159 with brain metastases) were included from 41 centers, which covered 75% of French pembro EAP. 79 pts (13%) achieved CR, among whom 68 (10%) stopped pembro for CR. Compared with the remaining 619 pts surveyed, these 68 pts had lower baseline serum LDH levels (54.5% vs 73.8%, respectively, were normal, p = 0.016), lower ECOG PS (ECOG 0 for 298 (52.6%) and 54 (80.6%), respectively, p = 0.001), and fewer metastatic sites (p = 0.003). Of note, 10% of these 68 pts had >3 metastatic sites, 10% had brain metastases, 53% had 2010 AJCC stage M1c melanoma, and 67% had received previous treatment for advanced melanoma (mainly ipilimumab). Frequency of BRAFV600, NRAS, and c-kit mutation status was not different between pts who did or did not achieve CR. Median duration on pembro in these 68 pts was 21.2 m (range: 2.5-48.4, SD 10.0). Pembro was used alone to achieve CR in 79% of pts, while 4% received concurrent radiotherapy alone, 10% concurrent surgery alone, and 6% both treatments. At the cut-off date (13/09/2018), after a median follow-up since pembro initiation of 36.3 m and of 15.3 m since pembro cessation (2-31, SD 8.3), only 3% of pts experienced melanoma recurrence. Median recurrence-free survival was not achieved. These 2 pts received radiotherapy, with one partial response achieved. 5 pts died, with 2 deaths unrelated to melanoma (1 lymphoma, 1 chylothorax), 1 related to melanoma progression, and 2 of unknown causes.


In this large real-life cohort, 10% of pts reached CR and discontinued pembro. All but 3% were recurrence-free after a median 15.3 m of treatment, thus validating the discontinuation of anti-PD1 in complete responders.

Clinical trial identification

CCTIRS, #15.640.

Editorial acknowledgement

RIC-Mel network and their team.

Legal entity responsible for the study

MSD France.


MSD France.


P. Saiag: Honoraria (self), Advisory / Consultancy: MSD. L. Mortier: Honoraria (self), Advisory / Consultancy: MSD. C. Dutriaux: Honoraria (self), Advisory / Consultancy: MSD. L. Benmahammed: Full / Part-time employment: MSD. O. Morsli: Full / Part-time employment: MSD. C. Train: Full / Part-time employment: ClinSearch. A. Spampinato: Full / Part-time employment: MSD. M.T. Leccia: Honoraria (self), Advisory / Consultancy: MSD. N. Meyer: Advisory / Consultancy: MSD. J.J. Grob: Honoraria (self), Advisory / Consultancy: MSD.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.